MX2017003140A - Tratamiento de los sintomas asociados a terapia privacion de androgenos. - Google Patents

Tratamiento de los sintomas asociados a terapia privacion de androgenos.

Info

Publication number
MX2017003140A
MX2017003140A MX2017003140A MX2017003140A MX2017003140A MX 2017003140 A MX2017003140 A MX 2017003140A MX 2017003140 A MX2017003140 A MX 2017003140A MX 2017003140 A MX2017003140 A MX 2017003140A MX 2017003140 A MX2017003140 A MX 2017003140A
Authority
MX
Mexico
Prior art keywords
treatment
androgen deprivation
deprivation therapy
associated symptoms
therapy associated
Prior art date
Application number
MX2017003140A
Other languages
English (en)
Inventor
Thomas Benson Charles
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2017003140A publication Critical patent/MX2017003140A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invención proporciona un método para tratar los síntomas asociados con la terapia de privación de andrógenos, que comprende administrar a un paciente que necesita dicho tratamiento una cantidad eficaz de un compuesto de la fórmula I, o una sal farmacéuticamente aceptable del mismo. (ver Fórmula).
MX2017003140A 2014-09-11 2015-09-08 Tratamiento de los sintomas asociados a terapia privacion de androgenos. MX2017003140A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462049192P 2014-09-11 2014-09-11
PCT/US2015/048801 WO2016040234A1 (en) 2014-09-11 2015-09-08 Treatment of androgen deprivation therapy associated symptoms

Publications (1)

Publication Number Publication Date
MX2017003140A true MX2017003140A (es) 2017-05-23

Family

ID=54151401

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017003140A MX2017003140A (es) 2014-09-11 2015-09-08 Tratamiento de los sintomas asociados a terapia privacion de androgenos.
MX2021014120A MX2021014120A (es) 2014-09-11 2017-03-09 Tratamiento de los sintomas asociados a terapia privacion de androgenos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021014120A MX2021014120A (es) 2014-09-11 2017-03-09 Tratamiento de los sintomas asociados a terapia privacion de androgenos.

Country Status (23)

Country Link
US (4) US10758515B2 (es)
EP (2) EP3375444A1 (es)
JP (4) JP6893171B2 (es)
KR (5) KR20170040338A (es)
CN (4) CN106794178A (es)
AP (1) AP2017009795A0 (es)
AU (2) AU2015315431C1 (es)
BR (2) BR122018007412B1 (es)
CA (2) CA2956514C (es)
EA (2) EA034553B1 (es)
ES (1) ES2779978T3 (es)
HK (1) HK1252811A1 (es)
IL (3) IL279209B2 (es)
JO (2) JOP20180072A1 (es)
MA (1) MA45416A (es)
MX (2) MX2017003140A (es)
MY (2) MY195767A (es)
NZ (1) NZ728612A (es)
SG (2) SG11201701630VA (es)
TW (1) TWI616201B (es)
UA (1) UA120099C2 (es)
WO (1) WO2016040234A1 (es)
ZA (1) ZA201802680B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
US20180185347A1 (en) * 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
AU2021213297A1 (en) * 2020-01-27 2022-08-18 Eirgen Pharma Ltd. Tetrahydrocyclopenta[b]indole compounds for the treatment of renal disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1592658B1 (en) * 2003-01-13 2013-04-24 University of Tennessee Research Foundation Large-scale synthesis of selective androgen receptor modulators
US9889110B2 (en) * 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
AR060974A1 (es) 2006-05-31 2008-07-23 Glaxo Group Ltd Compuesto de 4-piridinona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende, proceso para su preparacion y proceso para la preparacion de un compuesto intermediario de utilidad en el anterior
EA200900203A1 (ru) * 2006-07-19 2009-06-30 Огайо Стейт Юниверсити Рисерч Фаундейшн Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
US7443672B2 (en) 2006-10-03 2008-10-28 Fu Zhun Precision Industry (Shen Zhen) Co., Ltd. Video graphics array (VGA) card assembly
UA98777C2 (en) * 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
TW200918521A (en) 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
US8420624B2 (en) 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
BRPI0821090B8 (pt) 2007-12-21 2021-05-25 Ligand Pharm Inc moduladores seletivos de receptores de androgênio (sarms) e uso do mesmo
WO2009140448A1 (en) * 2008-05-16 2009-11-19 Eli Lilly And Company Tetrahydrocyclopenta[b]indole androgen receptor modulators
WO2009155481A1 (en) * 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
AR078862A1 (es) * 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
CN102234287B (zh) * 2010-04-26 2015-08-05 上海阳帆医药科技有限公司 硝基咪唑类化合物、其制备方法和用途
JP2012149054A (ja) * 2010-12-27 2012-08-09 Dainippon Sumitomo Pharma Co Ltd Ｎ−置換−環状アミノ誘導体からなる医薬
TWI638814B (zh) 2012-10-31 2018-10-21 富山化學工業股份有限公司 新穎之胺衍生物或其鹽
WO2015086519A1 (en) * 2013-12-09 2015-06-18 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of tnf activity
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين

Also Published As

Publication number Publication date
IL250291A0 (en) 2017-03-30
HK1252811A1 (zh) 2019-06-06
CA2956514C (en) 2023-04-18
US20200390744A1 (en) 2020-12-17
MX2021014120A (es) 2022-01-04
UA120099C2 (uk) 2019-10-10
SG10201809673RA (en) 2018-12-28
JO3609B1 (ar) 2020-08-27
EP3191094B1 (en) 2020-02-19
IL258651B (en) 2021-02-28
CA2956514A1 (en) 2016-03-17
BR122018007412B1 (pt) 2022-08-23
IL258651A (en) 2018-06-28
WO2016040234A1 (en) 2016-03-17
EA034553B1 (ru) 2020-02-19
TW201618782A (zh) 2016-06-01
JOP20180072A1 (ar) 2019-01-30
IL250291B (en) 2020-09-30
AU2018202714B2 (en) 2019-06-20
SG11201701630VA (en) 2017-03-30
KR20170040338A (ko) 2017-04-12
IL279209B2 (en) 2023-02-01
KR102024493B1 (ko) 2019-09-23
JP2017527584A (ja) 2017-09-21
MY198753A (en) 2023-09-23
BR112017002449A2 (pt) 2017-12-05
CN113521068A (zh) 2021-10-22
AP2017009795A0 (en) 2017-03-31
KR102619415B1 (ko) 2024-01-02
KR20190015628A (ko) 2019-02-13
JP2019089795A (ja) 2019-06-13
CA3067289A1 (en) 2016-03-17
BR112017002449B1 (pt) 2022-08-09
IL279209A (en) 2021-01-31
KR20210083370A (ko) 2021-07-06
NZ728612A (en) 2018-03-23
JP2022000432A (ja) 2022-01-04
EP3375444A1 (en) 2018-09-19
ES2779978T3 (es) 2020-08-21
MY195767A (en) 2023-02-10
EA201790220A1 (ru) 2017-07-31
EA033606B1 (ru) 2019-11-08
AU2015315431A1 (en) 2017-03-09
ZA201802680B (en) 2020-08-26
CN108440497A (zh) 2018-08-24
EA201891008A3 (ru) 2019-03-29
AU2015315431B2 (en) 2018-03-08
KR20220132669A (ko) 2022-09-30
US20240148694A1 (en) 2024-05-09
CA3067289C (en) 2023-04-04
JP7349480B2 (ja) 2023-09-22
EP3191094A1 (en) 2017-07-19
AU2015315431C1 (en) 2018-08-02
CN113651797A (zh) 2021-11-16
JP6893171B2 (ja) 2021-06-23
KR20180041268A (ko) 2018-04-23
US10799478B2 (en) 2020-10-13
MA45416A (fr) 2019-04-24
IL279209B (en) 2022-10-01
JP2023145479A (ja) 2023-10-11
TWI616201B (zh) 2018-03-01
AU2018202714A1 (en) 2018-05-17
US10758515B2 (en) 2020-09-01
JP6938550B2 (ja) 2021-09-22
US20190111039A1 (en) 2019-04-18
CN106794178A (zh) 2017-05-31
EA201891008A2 (ru) 2018-09-28
US20170172992A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2015012866A (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
BR112016014410A2 (pt) terapia de combinação com vacina de neoantígeno
MX2015014596A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer.
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
PH12017500493A1 (en) Combination therapy
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
PH12015502302A1 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
MX2016002479A (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MX2016016388A (es) Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña.
MX2016004967A (es) Tratamiento para cancer pancreatico.
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
PH12014502065A1 (en) Vesicular formulations
MX2018001684A (es) Metodo de curacion de heridas.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
IN2014DE00818A (es)
PH12014000105A1 (en) Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds
IN2014DE00822A (es)

Legal Events

Date Code Title Description
FG Grant or registration